NCT01246453View on ClinicalTrials.gov

Efficacy and Security of Intrapleurally Alteplase vs Urokinase for the Treatment of Complicated Parapneumonic Effusion and Empyema

PHASE4CompletedINTERVENTIONAL

Enrollment

204

Participants

Timeline

Start Date

December 31, 2003

Primary Completion Date

December 31, 2010

Study Completion Date

December 31, 2010

Conditions

Empyema, PleuralPleural EffusionPleural Diseases

Interventions

DRUG

Intrapleurally Alteplase vs Intrapleurally Urokinase

Alteplase 10 mg and urokinase 100000 intrapleurally administered, once daily for three days and if necessary 6 days

Trial Locations (2)

5

Hospital Vall d'Hebron, Barcelona

Unknown

Hospital Arnau de Vilanova, Lleida

All Listed Sponsors

lead

Hospital Universitari Vall d'Hebron Research Institute

OTHER

NCT01246453 - Efficacy and Security of Intrapleurally Alteplase vs Urokinase for the Treatment of Complicated Parapneumonic Effusion and Empyema | Biotech Hunter | Biotech Hunter